XI'AN, SHAANXI PROVINCE, CHINA, January 20, 2026 /EINPresswire.com/ -- As global demand for clean-label, functional, ...
Market valued at $46.59B in 2024, projected 7.31% CAGR growth driven by bio-based adoption, detergent demand, and ...
The enthalpy of BioCool exceeds 200 J/g compared to the enthalpy other solutions on the market between 120–180 J/g.
A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...
Plenty of analysts on Wall Street think so. The company boasts an average price target of $93.39 (according to Yahoo! Finance ...
Initiation of phase 1 portion of the trial planned in 2H 2026-Phase 2 portion of the trial will initiate development of the elraglusib tablet in ...
The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approvalRecent articles highlight the growing ...
Stability is a critical factor in drug formulation, with implications for product quality, lifecycle management, and ...
Lipocine has announced the completion of enrolment and participant dosing in its Phase III clinical trial investigating LPCN ...
Opinion
3dOpinion
Global Times: Viewing strategic formulation of 15th Five-Year Plan from 'two overall situations'
Coordinating the "two overall situations" is an important manifestation of the standpoints, viewpoints, and methods that run through Xi Jinping Thought on Socialism with Chinese Characteristics for a ...
Orphai Therapeutics Inc. ("Orphai"), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with diseases of significant unmet need, today announced that ...
WELLESLEY HILLS, Mass. - Climb Bio, Inc. (NASDAQ:CLYM) announced Thursday that it has dosed the first patients in its budoprutug PrisMN Phase 2 trial for primary membranous nephropathy (pMN) and in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results